Introduction {#sec0005}
============

The mosquito-borne flavivirus Japanese encephalitis virus (JEV) accounts for an estimated 68,000 cases of Japanese encephalitis and 709,000 disability-adjusted life years annually ([@bib0255], [@bib0130]). Japanese encephalitis virus (JEV) primarily affects children in rural areas when JEV-infected mosquitoes feed on humans rather than their primary amplifying hosts, pigs, or reservoir hosts, i.e., aquatic birds ([@bib0570]). Sustained efforts from international agencies have supported the introduction of immunization programs into routine health control schedules in countries with endemic JEV transmission, [Table 1](#tbl0005){ref-type="table"} ([@bib0330]). The evidence suggests that vaccination has had an impact on JE incidence ([@bib0330], [@bib0365], [@bib0850], [@bib0565], [@bib0775], [@bib0865], [@bib0530]). However, JEV remains a leading cause of neurological infection in endemic countries, and the Joint World Health Organisation (WHO)/United Nations Children\'s Fund (UNICEF) surveillance data do not substantiate the improvements cited in the past ten years, with sustained numbers of reported patients over this period, see [Figure 1](#fig0005){ref-type="fig"}.Table 1Country-specific data on the introduction of Japanese encephalitis virus vaccine in JEV endemic countries. Data adapted from the CDC report by Heffelfinger et al. 2017 and updated with WHO surveillance data ([@bib0330], [@bib0825], [@bib0840]).Table 1CountryWHO regionVaccine in schedule (2019)JE immunization programYear introduced subnationallyYear introduced nationallyScheduled age (months) for vaccineVaccine used in immunisation programAustraliaWPROYesRisk areas: outer islands of Torres Straitsn/an/a12Live-recombinantBangladeshSEARONoNonen/an/a----BhutanSEARONoNonen/an/a----Brunei DarussalamWPRONoNonen/an/a----CambodiaWPROYesNational200920159Live-attenuatedPeople's Republic of ChinaWPROYesNational; excluding Qinghai, Tibet, Xinjiang, and Hong Kong which do not have endemic transmission2003[\*](#tblfn0005){ref-type="table-fn"}20088Live-attenuatedDPR of KoreaSEARONoNone; JEV vaccination campaign in 2016n/an/a----IndiaSEAROYesSubnational2007n/a9--11Live-attenuatedIndonesiaSEAROYesSubnational: Bali2018n/a----JapanWPROYesNational\<2002\<20076Inactivated vero cell derivedLao PDRWPROYesNational201320159--11Live-attenuatedMalaysiaWPROYesSubnational: Sarawak and Sabah2002n/a9Live-recombinantMyanmarSEAROYesNationaln/a2018----NepalSEAROYesNational2007201712Live-attenuatedPakistanEMRONoNonen/an/a----Papua New GuineaWPRONoNonen/an/a----PhilippinesWPROYesSubnational: Regions I-III, and the Cordillera Administrative Region2018n/a----Republic of KoreaWPROYesNationaln/a\<200212Live-attenuated, Live-recombinant, Inactivated vero cell and mouse brain derivedRussian FederationEURONoNonen/an/a----SingaporeWPRONoNonen/an/a----Sri LankaSEAROYesNational2001201112Live-attenuatedRepublic of ChinaWPROYesNational1963196815Inactivated mouse brain derivedThailandSEAROYesNationaln/a\<200212Live-attenuated and Live-recombinantTimor-LesteSEARONoNonen/an/a----VietnamWPROYesNational\<2002201512Inactivated mouse brain derived[^1]Figure 1Number of JE cases reported annually over the last decade based on WHO/UNICEF surveillance ([@bib0845]). Data include probable\* and laboratory-confirmed cases reported by JEV endemic countries. \*WHO definition of a probable case ([@bib0710]) = A case that meets the clinical case definition for acute encephalitis syndrome (AES) that occurs in close geographical and temporal relationship to a laboratory-confirmed case of JE, in the context of an outbreak. Note that these data represent only reported cases, and are not considered to be an accurate representation of global JE incidence. The weaknesses of these data are discussed in the main text.Figure 1

JE cases reported to WHO/UNICEF have significant limitations. For example, increased awareness of the disease and access to laboratory capacity may contribute to increased case reporting. Conversely, surveillance data are likely to represent only a small proportion of patients ([@bib0495]). This is particularly relevant for JE, occurring predominantly in rural areas lacking diagnostic capacity ([@bib0785]). There are no rapid or point-of-care tests for JE in clinical use ([@bib0685]), and the WHO recommended standard diagnostic assay is an ELISA test that requires trained professionals, appropriate resources, and several hours for the results of the tests to be obtained ([@bib0805]). In a survey performed by WHO/UNICEF in 2017, 21 countries responded, of which 11 met the minimum surveillance standards ([@bib0835], [@bib0830]). Equally, there are problems of specificity of the most widely used diagnostic test, JE MAC-ELISA ([@bib0230]). This is an increasing issue, with increasing endemicity of other flaviviruses and vaccination coverage.

The reasons for the persistence of JE as a public health problem are complex and multifactorial. A fundamental principle that must be kept in mind is that JE is a zoonotic infection; human immunization will never eradicate it in the natural environment and therefore sustained vaccination coverage is necessary. However, in countries that do have vaccination programs, they are not necessarily uniformly implemented nationwide, and in some areas, vaccine coverage is sub-optimal. While there are many reasons for inadequate coverage, this remains a neglected aspect of JE vaccination programs ([@bib0535]). Furthermore, immunization strategies are constrained by the absence of adequate diagnostic capacity to investigate the burden of disease, the impact of vaccination ([@bib0740]), and the dynamic epidemiology of JE. For example, in common with other emerging arboviruses ([@bib0295]), JE has the propensity to emerge and become established in new geographical regions ([@bib0500]). In recent years there have been increasingly frequent reports of cases in peri-urban and urban areas ([@bib0295]), as well as new regions such as Rajasthan, India.

Moreover, evidence for autochthonous transmission of JEV in Angola was recently reported ([@bib0700]). JEV RNA has also recently been detected in birds in Italy ([@bib0590]). This most likely represents the globally increased movement, via transportation, of animals and goods. Increased pig farming in urban areas of Asian countries also impacts on virus amplification. Finally, the live attenuated vaccine in widespread use is based on JEV genotype 3, even though in recent decades, there has been large-scale genotype displacement to genotype 1 ([@bib0800]), and evidence of detection of genotype 5 ([@bib0135]).

Accordingly, we performed a comprehensive review of the evolution of current diagnostic tests for JE. We tackled this by performing a systematic review of published laboratory-confirmed symptomatic cases of JE in humans, and extracted data on the laboratory procedures employed. We also appraised novel tests either under development or conceptually applicable for future diagnostic purposes. Data analysis informed our discussion on future perspectives for research.

Methods {#sec0010}
=======

Searches were performed in the Web of Science and PubMed using the text word term \'Japanese encephalitis\' up to 13th October 2019. The abstracts were reviewed, and a full text was obtained for those potentially containing information on human cases of JE in the English language. The full-text articles were then reviewed for those reporting symptomatic human cases of laboratory-confirmed JE. The search was limited to JE cases confirmed during the acute illness or hospitalization rather than seroprevalence, with geographic information at least to the country of onset of illness, and temporal information at least to the year of diagnosis. Data were extracted on details of the diagnostic confirmation of JE cases. A JE case was classified according to the confirmatory level ([@bib0255], [@bib0130], [@bib0570], [@bib0330]) developed from existing WHO and CDC criteria, where 1 provides the highest level of confidence based on the diagnostic test used, as illustrated in [Table 2](#tbl0010){ref-type="table"}.Table 2Diagnostic criteria used to assess JE laboratory-confirmed patients.[\*](#tblfn0010){ref-type="table-fn"}Table 2Level 1JEV RNA detected in any specimen by RT-PCR.Virus isolation by inoculation of any specimen in cell culture or animal with characteristic cytopathic effect and confirmation by detection of JEV RNA or virus antigen.JEV virus antigen detected from brain tissue or CSF by immunofluorescence or immunohistochemistryLevel 2Seroconversion or ≥ 4x rise in anti-JEV Ab by seroneutralization or detection of neutralizing antibody in CSF; Samples should be tested alongside other endemic flaviviruses (e.g., dengue viruses)Level 3Anti-JEV IgM detected in CSF; Samples should be tested alongside other endemic flaviviruses (e.g., dengue viruses)Seroconversion or 4x rise in anti-JEV Ab HI, CF, IFA, or seroconversion by ELISA; Samples should be tested alongside other endemic flaviviruses (e.g., dengue viruses).Level 4Anti-JEV IgM detected in serum in one sample (acute/convalescent), or seroneutralisation tested in one sample or single high titer HI/CF/IFA; Samples must be tested alongside other endemic flaviviruses (e.g., dengue viruses)[^2][^3]

Results {#sec0015}
=======

This review identified 205 studies in 22 countries in which a total of 20,212 JE patients were confirmed by laboratory tests; see [Figure 2](#fig0010){ref-type="fig"} for the PRISMA flow diagram. Patients were predominantly diagnosed in Asia, with a suggested case of autochthonous transmission diagnosed in Angola. The studies incorporated a variety of methods for the diagnostic tests, including conventional and novel approaches, as summarised in [Table 3](#tbl0015){ref-type="table"}. The data do not provide evidence of change in the certainty of diagnosis through time, see [Table 4](#tbl0020){ref-type="table"}.Figure 2PRISMA flow diagram.Figure 2Table 3Diagnostic methods used for evidence of Japanese encephalitis virus infection.Table 3Diagnostic methodConfirmatory levelAdvantageDisadvantage[Virus detection:]{.ul}\
Virus Isolation:\
Inoculation of patient samples into animals\
Inoculation of patient samples onto primary chick or duck embryo cells, and cell lines including Vero, LLCMK, C6/36, MRC and AP61\
Inoculation of patient samples into mosquitoes\
Virus antigen detection:\
Reverse passive haemagglutination\
Immunofluorescence microscopy\
Staphylococcal coagglutination tests using polyclonal or monoclonal antibodies\
Monoclonal antibody/immunogold/silver-staining (M-IGSS)\
ELISA to detect a viral protein (NS1)Level 1Direct detection of the virus or viral protein and high specificity\
Viral isolation provides molecular epidemiological dataLow sensitivity, laborious and viral isolation requires biosafety 3 laboratory capacity[Molecular detection:]{.ul}\
Conventional RT-PCR\
Real-time RT-PCR\
Nested PCR\
Specific vs. pan-flavivirus\
Multiplex PCR\
Next-generation sequencingLevel 1Direct detection of the viral genome, provides high specificity and additional molecular epidemiological dataLow sensitivity[Antibody detection:]{.ul}\
Seroneutralization\
IgM antibody capture ELISA\
Avidin biotin system\
Biotin-labeled immunosorbent assay\
Nitrocellulose membrane-based immunoglobulin M capture dot enzyme immunoassay\
Haemagglutination inhibition +/- sucrose gradient density centrifugation and 2-mercaptoethanol treatment (2-ME) to detect IgM\
Complement fixation test\
Single radial hemolysisLevel 2 for seroconversion demonstrated by neutralization\
Level 3 for detection of IgM in CSF and for seroconversion or ≥4x rise in Ab titer; Level 4 for detection of Ab detection in a single sampleGood sensitivity\
Good specificity for primary infection\
Commercial kit available\
Good sensitivityCross-reaction with other flaviviruses\
Requires paired samples\
Laborious\
Difficult to interpret in secondary infection\
Limited specificity\
Cross reaction with other flaviviruses\
Requires paired samples\
Difficult to interpret in secondary infectionTable 4Temporal changes in JE diagnostic confirmatory level. Percentage of symptomatic human JE cases reported in the English-language literature in blocks of five years that were confirmed by laboratory testing Level 1-4[\*](#tblfn0015){ref-type="table-fn"}.Table 4![](fx1.gif)[^4]

Overview of JEV diagnostic testing {#sec0020}
==================================

The first isolation of JEV was in 1934 when Hayashi demonstrated that a filterable agent inoculated into monkeys produced encephalitis ([@bib0325]). The experiment was performed using homogenized brain obtained at post-mortem from a fatally-infected child who presented with encephalitis in Tokyo during the 1924 epidemic. Early studies relied on clinicopathological correlates in infected humans, when compared with those observed following animal inoculation of post-mortem samples. Subsequently, hamster, porcine, and human cell culture systems were developed, which revealed cytopathic effects when inoculated with JEV-infectious specimens ([@bib0525], [@bib0285]). As these procedures improved, mosquitoes and mosquito-cell cultures were added to the resources for isolation and identification of JEV ([@bib0270], [@bib0380]). Cerebrospinal fluid (CSF) and other body fluids were also included for analysis ([@bib0410], [@bib0415]). Subsequently, JEV antigen detection procedures including complement fixation, immunofluorescence microscopy of cells in CSF, reverse passive haemagglutination, and staphylococcal coagglutination ([@bib0510], [@bib0600], [@bib0320], [@bib0515]) were added to the list of diagnostic tests. Nonetheless, assays involving direct virus detection are minimally useful for the diagnosis of JE as the level of viremia is usually low, and the virus is detectable only briefly early in the infection ([@bib0405]).

In the mid-twentieth century, investigation of the antigenic properties of JEV soon led to the development of serological assays, including complement fixation ([@bib0150]), inhibition of haemagglutination ([@bib0190]), and virus neutralization tests ([@bib0650], [@bib0690]). Early reports of human infection in 1947 used a seroneutralization technique in which a patient sample was mixed with virus and inoculated into mice ([@bib0650], [@bib0655], [@bib0435]). In 1941, Casals and Palacios published a report on the application of the complement fixation technique ([@bib0155]). The method was used for many years, although it was insensitive, particularly during the acute illness ([@bib0635]). In 1958, Clarke and Casals published a report on the application of the haemagglutination inhibition test (HI) ([@bib0190]). The principle exploits the fact that JEV envelope protein agglutinates erythrocytes. Anti-JEV antibodies, developed following infection, bind to JEV protein and thus prevent erythrocyte agglutination, hence the term haemagglutination-inhibition. This remained the method of choice for JE diagnosis, by serological methods, for many years ([@bib0545], [@bib0220], [@bib0060], [@bib0750]) and was subsequently adapted as a more convenient microtiter method ([@bib0270], [@bib0690], [@bib0310]). However, limitations in the sensitivity and specificity of the assay were recognized by Clarke and Casals ([@bib0190]). Moreover, the test relies on the combined paired results obtained from acute and convalescent serum samples, thus taking weeks for confirmation ([@bib0115]). Other serological methods, such as single-radial hemolysis ([@bib0180], [@bib0235], [@bib0290]), were also introduced. However, inadequacies were readily acknowledged, and it was accepted practice to perform these tests in parallel with others, thus increasing the workload and extending the time for results to be obtained ([@bib0105], [@bib0140]).

The plaque-reduction neutralization test (PRNT) was subsequently developed as the gold-standard for JE diagnosis, using paired acute and convalescent sera and comparison with other endemic flaviviruses, and it remains so today ([@bib0340]). The demonstration of increasing anti-JEV neutralizing antibody titer in the convalescent serum and the absence, or at least fourfold lower titer for neutralizing antibodies against control-related flaviviruses, provides a robust diagnosis. However, this is laborious, time-consuming, and requires high-level containment facilities for safe manipulation of infectious JEV in cell culture. Mainly for these reasons, the anti-JEV IgM capture ELISA (JEV MAC-ELISA) was developed during the 1980s and has been incorporated as the WHO standard procedure for JE diagnosis ([@bib0110], [@bib0820]). Although commercial JEV MAC ELISAs are manufactured, they may be hard to access in endemic countries (for example, there is no supplier in Laos), relatively expensive, and require costly ELISA readers and significant technical training. The performance of the kit requires specialized laboratory equipment, and thus are by no means point-of-care tests. In addition, field studies suggest that the sensitivity is 50-70% ([@bib0620]), and concerns have been raised regarding the diagnostic specificity ([@bib0230]). In the last two decades, there has been increased availability of molecular testing, providing crucial data on molecular epidemiology. As well, the aforementioned low and brief viremia limits the role of screening for JEV RNA for diagnostic purposes. Similarly, advances in techniques such as near-atomic resolution cryo-electron microscopy contribute to our understanding of the detailed viral structure, but not to the routine detection of human infection ([Figure 3](#fig0015){ref-type="fig"}).Figure 3Chronological representation of discoveries related to the detection of Japanese encephalitis virus infection ([@bib0525], [@bib0690], [@bib0435], [@bib0155], [@bib0635], [@bib0545], [@bib0160], [@bib0605]).Figure 3

Specific findings of JEV diagnostics review {#sec0025}
===========================================

Studies reporting on the use of seroneutralization, IgM ELISA and RT-PCR are discussed below, since these assays are, at present, the ones most widely incorporated into clinical diagnostics.

Seroneutralization assays: Thirty-two studies identifying evidence of JE using neutralization assays (see [Table 5](#tbl0025){ref-type="table"}) are included, of which 15 clearly performed tests on acute and convalescent sera, indicating seroconversion ([@bib0140], [@bib0575], [@bib0170], [@bib0175], [@bib0025], [@bib0030], [@bib0335], [@bib0355], [@bib0450], [@bib0465], [@bib0480], [@bib0550], [@bib0555], [@bib0665], [@bib0715], [@bib0730], [@bib0760]). These were largely PRNT (14 articles) and/or a microtiter modification in a 96-well plate (4 articles). Three studies performed focus-reduction seroneutralization tests (FRNT), a high-throughput modification of the PRNT involving 96-well plates and an immunocalorimetric assay for end-point determination. Other studies did not describe their methods in detail or cite references to support them. Eleven reported JEV strain used ([@bib0650]; [@bib0140]; [@bib0480]; [@bib0680]; [@bib0065]; [@bib0610]; [@bib0210]; [@bib0035]; [@bib0440]; [@bib0660]; [@bib0090]): they were all genotype 3 viruses, except for one that reported the use of genotype 1 and 3 strains to enable neutralization-based genotype differentiation ([@bib0680]). Five studies indicated JEV inoculating dose: the end-point was identified by visual inspection of the cytopathic effect (CPE), staining, or immunofluorescence. All reports appeared to use two-fold dilutions of serum samples, between 1:10 to 1:640 or higher. In terms of quality control, three studies detailed other viruses used, and the use of replicates. Five studies ([@bib0650]; [@bib0140]; [@bib0610]; [@bib0035]; [@bib0660]) included the use of other flaviviruses such as dengue viruses, West Nile virus, or yellow fever virus.Table 5Details of seroneutralization testing.Table 5ReferenceCountry samplingCountry testingTechniqueJEV StrainOther viruses testedCellsVirus DoseEnd-pointSamples testedAlgorithm for seroneutralisation[@bib0655])Republic of KoreaJapanMice inoculationG3 (Nakayama), human brain, Tokyo, Japan, 1935 (EF571853)NRIntracerebral and intraperitoneal inoculation in miceNRNRAcute and f/up serum, and CSFAll samples[@bib0660])ChinaJapanMice inoculationG3 (Nakayama), human brain, Tokyo, Japan, 1935 (EF571853)NRIntracerebral and intraperitonealNRNRAcute and f/up serum, and CSFAll samples[@bib0650])JapanJapanMice inoculationG3 (Nakayama), human brain, Tokyo, Japan, 1935 (EF571853)NRIntracerebral and intraperitonealNRNRAcute and f/up serum, and CSFAll samples[@bib0240])VietnamVietnamPRNTNRDENVNRNRNRNRNR[@bib0070])ThailandThailandPRNTG3 strain (Nakayama), human brain, Tokyo, Japan, 1935 (EF571853)DENV 4LLC-MK2 cells50-100 PFUNRAcute and f/up serumNR[@bib0350])ThailandThailandNRNRNRNRNRNRNRNR[@bib0140])MalaysiaMalaysiaPRNTG3 strain (Nakayama), human brain, Tokyo, Japan, 1935 (EF571853)DENV 2 (16681 strain)*Aedes albopictus* C6/36 cellsNR50%[\*](#tblfn0020){ref-type="table-fn"}Acute and f/up serumConfirmatory testing after positive MAC-ELISA[@bib0575])Sri LankaSri LankaMicrotitre VNTNRNRPorcine stable (PS) kidney cellsNR80%[\*](#tblfn0020){ref-type="table-fn"}Serum (NR if acute and/or f/up)NR[@bib0815])IndonesiaSwedenPRNTNRNRNRNR80%[\*](#tblfn0020){ref-type="table-fn"}Acute and f/up serumNR[@bib0335])ChinaU.S.A.PRNTNRNRNRNRNRCSF, Acute and f/up serumAll samples[@bib0215])IndiaIndiaMicrotitre VNTG3 (P20778/P20), human brain, Vellore, India, 1958 (AF080251)NRPorcine stable (PS) kidney cells100 TCID 50100%[\*](#tblfn0020){ref-type="table-fn"}CSFAll samples[@bib0675])JapanJapanFRNTNRYFVBHK-21 cellsNR50%[\*](#tblfn0020){ref-type="table-fn"}CSF, Acute and f/up serumAll samples[@bib0755])IndiaIndiaNRNRNRNRNRNRNRNR[@bib0200])ChinaNew ZealandNRNRNRNRNRNRAcute and f/up serumNR[@bib0170])ThailandU.S.A.NRNRNRNRNRNRAcute and f/up serumNR[@bib0555])IndonesiaIndonesiaPRNTNRNRNRNRNRSerum (NR if acute and/or convalescent)NR[@bib0470])ThailandFinlandPRNTNRDENV 2NRNRNRAcute and f/up serumNR[@bib0610])IndiaIndiaPRNTChimeriVax™-JEVChimeriVax™-DENV 2Vero cellsNRNRCSFConfirmatory testing after positive or equivocal MAC-ELISA[@bib0765])CambodiaCambodiaPRNTNRNRVero cellsNRNRNRNR[@bib0025])Papua New GuineaAustraliaPRNTNRNRNRNRNRNRNR[@bib0355])BangladeshU.S.A.PRNTNRNRNRNR90%[\*](#tblfn0020){ref-type="table-fn"}NRNR[@bib0175])U.S.A. (Travellers from the Philippines and Thailand)U.S.A.NRNRNRNRNRNRCSFNR[@bib0090])IndiaIndiaMicrotitre VNTG3 strain (P20778/P20), human brain, Vellore, India, 1958 (AF080251)NRBHK-21 cells100 TCID50 in 50 μL50%[\*](#tblfn0020){ref-type="table-fn"}Acute and f/up serumPatients with paired serum available after MAC-ELISA tested[@bib0465])Republic of KoreaRepublic of KoreaNRNot reportedNRNRNRNRAcute and convalescent serumConfirmatory testing after positive MAC-ELISA/HI/IIF.[@bib0455])Canada (Traveller from Thailand)CanadaNRNRWNV and DENVNRNRNRCSF, Acute and convalescent serumAll samples[@bib0345])China, Taiwan, Republic of KoreaU.S.A.NRNRNRNRNRNRAcute and f/up serumNR[@bib0035])IndiaIndiaMicrotitre VNTG3 (P3), human brain, Bankura, India, 1973 (AB379813/Z34095)WNVPorcine stable (PS) kidney cells100 TCID5050%[\*](#tblfn0020){ref-type="table-fn"}Acute serumAll acute serum[@bib0615])NepalU.S.PRNTNRDENV, WNV, and Powassan viruses.NRNRNRNRConfirmatory testing after positive or equivocal MAC-ELISA[@bib0680])LaosJapanFRNTNakayama (a pathogenic and vaccine strain, Tokyo, Japan, human brain, 1935, G3), Beijing-1 (a pathogenic and vaccine strain, Beijing, China, human brain, 1949, G3), P19-Br (an isolate, Chiang Mai, Thailand, human brain, 1982, G1), LaVS56 (an isolate, Vientiane, Lao PDR, swine sera, 1993, G1), and LaVS145 (an isolate, Vientiane, Lao PDR, swine sera, 1993, G1)DENV 1 (Hawaiian), 2 (New Guinea B), 3 (H-87), and 4 (H-241) and WNVBHK-21 cellsNR50%[\*](#tblfn0020){ref-type="table-fn"}Acute and f/up serumAll samples[@bib0480])ChinaChinaPRNTG3 strain (733913), human brain, Beijing, China, 1949 (AY243805/AY243844)NRBHK-21 cells100 PFUs90%[\*](#tblfn0020){ref-type="table-fn"}Acute and f/up serumAll serum[@bib0730])Republic of KoreaRepublic of KoreaNRNRNRNRNRNRNRNR[@bib0440])MyanmarMyanmarFRNT and PRNTG3 strain (JaOrS982), mosquitos, Japan, 1982 (NC_001437)DENV 1-4NRNRNRCSFNR[^5][^6]

Studies followed different algorithms for including neutralization in patient testing, but it was primarily performed to confirm equivocal cases in other serological tests. Acute and/or follow-up serum and/or CSF were tested. For studies that did report individual results, confirmation was rarely achieved as there was either insufficient serum, failure to detect a four-fold rise of antibody titer in the convalescent serum, or cross-reactivity was detected with related viruses included as controls in the tests.

IgM ELISA: One hundred and sixty-three (80%) studies reported the results of tests using IgM MAC-ELISA methods. Notably, 115 of these studies tested both CSF and serum samples and presented results for the different body fluids separately. One hundred and twenty-two (74%) reported the method, of which 66 (40%) used in-house methods, and 33 (20%) used commercial kits. The primary in-house methods involved those described by [@bib0110]), [@bib0370]), the National Institute of Virology, Pune ([@bib0585]). Commercial kits were purchased from PanBio ([@bib0765]), Venture Technologies ([@bib0145]), XCyton Diagnostics Ltd. ([@bib0095]), and Shanghai B&C Biological Technology Co. Ltd. ([@bib0245]). There was minimal reporting of quality control measures such as control specimens and repeat testing of positives; 46 (28%) reported following the manufacturer's instructions. In total, 7,584 JE patients (38%) were diagnosed by MAC-ELISA in serum and/or CSF, i.e., results for the different body fluids were not reported separately, with 3,668 (18%) positive in CSF alone. Ninety-one (56%) studies using MAC-ELISA also reported testing for dengue virus infection to confirm specificity for JEV, i.e., they were not cross-reactive with dengue viruses.

Molecular tests: Forty-one studies (25%) reported the use of reverse transcription-polymerase chain reaction tests (RT-PCR), of which 13 (68%) described the methods used or cited corresponding references. These targeted various regions of JEV genome, including the capsid (C), pre-membrane (prM), envelope (E), non-structural (NS) proteins NS2A, NS3, NS5 and the untranslated regions (UTR). These studies reported the use of the conventional RT-PCR standard test, with nested or hemi-nested techniques, and real-time techniques (RT-qPCR) using hydrolysis probes or SYBR green. The studies reported the use of conventional RT-PCR either standard, with nested or hemi-nested techniques, and the real-time techniques (RT-qPCR) using hydrolysis probes or SYBR green. In total, 332 (1.7%) patients were positive when tested by RT-PCR.

Other tests: Fifty-eight (28%) studies reported the isolation of JEV *in vivo* or *in vitro*. Forty-two (20%) performed HI, 14 (7%) performed complement fixation, and seven (4%) performed indirect immunofluorescence assays. Two (1%) studies diagnosed cases by next-generation sequencing.

Discussion {#sec0030}
==========

This review reveals that current JE diagnostic techniques are confined mainly to those with a low confidence level, i.e., anti-JEV IgM detected in serum samples, or in which reported results do not differentiate between detection of anti-JEV IgM in CSF and serum. There is no doubt that the introduction of IgM ELISA testing in serum samples represents real progress. However, we are now much better informed about the limitations of relying on this method of detection. We also acknowledge as a limitation that the studies included in this review were performed in different settings, with different constraints, financial limitations, and resources available. Nonetheless, we highlight the need for both an improvement in the accuracy of routine laboratory diagnostics, and also the development of point-of-care tests to confirm cases in JE endemic areas that frequently have no laboratory capacity. Below, we discuss the existing assays in more detail.

Seroneutralization tests: Seroneutralization is considered the gold standard for the diagnosis of infections due to pathogenic viruses such as JEV, but in the published literature cited here, it was only performed in approximately 16% (32/205) of studies as laboratory confirmation. This is probably because performing seroneutralization is technically demanding and requires sufficient volumes of serum/CSF to enable the inclusion of control viruses and duplicates of each titration. Since JEV is a human pathogen with high individual risk, seroneutralization has to be performed in a biosafety level 3 laboratory, placing additional burdens on time, cost, and qualified personnel. Another potential complication may arise when sera from patients who have previously been exposed to JEV-related flaviviruses may contain higher titers against the closely related flaviviruses than against JEV ("doctrine of original antigenic sin") ([@bib0260]). For example, the titers of anti-YFV neutralizing antibodies were higher than anti-JEV neutralizing antibodies in JE patients who had previously received the yellow fever vaccine ([@bib0675]).

Similarly, in a study testing for West Nile virus and JEV, 18 patients' data remained equivocal due to high levels of antigenic cross-reactivity between these viruses ([@bib0035]). The neutralization test may only be strictly applicable as the gold-standard for vaccine efficacy studies when a baseline serum sample is compared with a convalescent sample taken at a fixed interval 1-3 months later. To confirm acute JEV, neutralization is an imperfect gold standard. Severe constraints on being able to arrange for sample testing by neutralization, and the results being interpretable without cross-reactive positivity due to other flaviviruses (which is relatively rare in JEV endemic areas), impede \'neutralization confirmation.\' The neutralization titers obtained may be affected by the particular strain of challenge virus utilized ([@bib0250]). A final issue with the neutralization test is the inability to detect non-neutralizing antibodies, thus potentially reducing the analytical sensitivity ([@bib0385]). Therefore, the practicalities of PRNT and diagnostic yield when testing field samples can be low, although the specificity is potentially high.

IgM ELISA: Anti-JEV IgM detection by MAC-ELISA is the WHO recommended standard diagnostic test, and 80% (163/205) of studies reported the use of a MAC-ELISA. It is recognized that JEV diagnosis by testing CSF provides considerably more reliable confirmation than the use of serum ([@bib0300]). However, obtaining acute and convalescent CSF and serum samples can be difficult, particularly in rural Asia where access is logistically tricky, and personnel and appropriate facilities are limited. Only 91 (56%) studies reported contemporaneous testing for anti-dengue-specific antibodies. There are issues in the accurate full reporting of results, both for the breakdown of which patients were diagnosed by testing CSF and/or serum, and contemporaneous testing for dengue-specific antibodies.

Reverse-transcription polymerase chain reaction assays (RT-PCR) for the detection of JEV RNA:

Diagnosis by the detection of the viral genome by DNA amplification generated by RT-PCR is a valuable addition to diagnostic procedures for RNA viruses. The test has high analytical sensitivity, is very specific, and can provide additional information that can be exploited to understand the molecular epidemiology of the detected virus. Nonetheless, JE cases are rarely confirmed (1.7% in this review) using RT-PCR technology, although this will undoubtedly increase in usage as point-of-care and automated methods are developed. Poor reporting of the techniques used in many publications hinders our ability to make comparisons of the efficacy of different methods (see [@bib0075]). There does appear to be higher analytical sensitivity in studies that used nested and hemi-nested techniques as compared to those using single RT-PCR; however, these techniques are notoriously prone to contamination, causing false-positive results. It is also recognized that the sensitivity of nucleic acid (and protein) detection will continue to increase as technology improves ([@bib0045], [@bib0870]). Evidence to suggest that this will be the case arises from the high cycle threshold (Ct) of patients that are confirmed, and the fact that blood donor transmission has been seen in WNV patients who were negative by RT-qPCR tests ([@bib0225]). The recent detection of JEV RNA in throat swabs of JE patients suggests that this non-invasive procedure may marginally improve diagnostic yield ([@bib0080]). There have now been two cases of JE, confirmed by RT-PCR, that were first identified by metagenomic next-generation sequencing (mNGS) ([@bib0705], [@bib0505]); the first detection of JEV RNA in human urine, and JEV detection in serum from an African patient with a co-YFV infection. The latter was not confirmed by an orthogonal method and remains questionable. Nonetheless, unbiased mNGS technology (see below), application, and reporting will continue to improve, and could potentially detect JEV in new locations ([@bib0100]).

Requirements of a new test for the detection of JEV infection

CNS infections are challenging syndromes to diagnose and treat, even in the most highly resourced centers ([@bib0390], [@bib0720]). It is estimated that they may be caused by \>100 different pathogens, including novel and emerging pathogens ([@bib0305]). Current approaches to diagnosis in routine clinical practice involves targeted strategies, suggesting that some (potentially treatable) infectious aetiologies are missed ([@bib0100]). Clinical diagnosis is rarely absolute, and confirmation requires access to appropriate laboratory facilities and personnel, lacking in many areas worldwide ([@bib0810]). While the analysis of brain biopsy material is the gold standard, it is not possible in most cases. Aetiological diagnosis usually involves an invasive lumbar puncture (LP) to obtain CSF, which in turn requires the appropriate clinical skills, infrastructure, and patient acceptability. Diagnostic assays are frequently difficult to interpret, may demonstrate poor accuracy and poor discrimination between previous vaccination or non-neurological JEV infection ([@bib0300]). Targeted research is needed to raise the bar for both the improvement in laboratory diagnostics as well as the development of point-of-care tests ([@bib0375]).

In clinical and epidemiological situations, the detection of JEV RNA can provide an invaluable indication of infection. The sensitivity of this test is, to a large extent, limited by a combination of the short period of viremia, the relatively low concentration of virus in CSF, and the fragility of RNA. The introduction of highly sensitive point-of-care tests that may be used to analyze multiple body fluids in parallel would partly resolve these challenges. Recently, there have been significant developments in highly sensitive molecular point-of-care tests for flaviviruses, such as reverse transcription loop-mediated isothermal amplification (RT-LAMP), reverse transcription recombinase polymerase amplification (RT-RPA), nucleic acid sequence-based amplification (NASBA), transcription-mediated amplification (TMA), helicase-dependent amplification (HDA), and nicking enzyme amplification reaction (NEAR) ([@bib0120], [@bib0275], [@bib0430], [@bib0520], [@bib0595], [@bib0860], [@bib0165], [@bib0315], [@bib0395], [@bib0425], [@bib0490], [@bib0445], [@bib0645], [@bib0725], [@bib0880], [@bib0005], [@bib0185], [@bib0735], [@bib0780], [@bib0640]). Microfluidics, chips, paper-based devices, and biosensors are also being developed ([@bib0560], [@bib0010], [@bib0015], [@bib0040], [@bib0795]).

For the time being, we will need to rely on serology for diagnostic confirmation. During the past three years, with the international focus on emerging flaviviruses following the chikungunya virus and theZika virus global epidemics, there have been intensified efforts to reduce cost, increase throughput, and improve specificity. These include the analysis of IgA ([@bib0020], [@bib0790], [@bib0195], [@bib0540], [@bib0625], [@bib0875], [@bib0360], [@bib0055], [@bib0050], [@bib0855]) and IgG subclasses ([@bib0540]), antibody avidity ([@bib0020], [@bib0205], [@bib0630], [@bib0770], [@bib0695]), incorporation of blocking agents, IgG depletion ([@bib0125]) and production of specific monoclonal antibodies for identification of specific viral epitopes ([@bib0885], [@bib0460], [@bib0580], [@bib0400], [@bib0265]). This recent work highlights the inherent challenges of serological techniques for JE identification. As Lindsey et al. describe, antigenic cross-reactivity between related viruses can make it virtually impossible to distinguish the cause of the infection ([@bib0485]). For example, cross-reactive IgM class antibodies may not be stimulated during a related secondary flavivirus infection. On the other hand, IgA may be produced during a secondary flavivirus infection, and a laboratory-defined 'seroconversion' might be detected following a secondary flavivirus infection by a related flavivirus.

Evidence suggests that the secreted viral JEV non-structural protein 1 (NS1) is present at very low concentrations in serum or CSF, unlike in dengue ([@bib0475], [@bib0420]). A novel alternative approach would be to analyze the host response, using transcriptomics or proteomics. However, questions of specificity and how these would be translated into point-of-care tests will require detailed investigation and the development of innovative methodologies.

In summary, while the diagnosis of JE has been possible for many years, it still requires specialized high-containment laboratories and appropriately trained scientists. Therefore, it cannot be reliably carried out in many resource-limited regions where JEV is endemic/epidemic. A fundamental pre-requisite in the public health strategy for the control of JE is lacking, that of a reliable and simple diagnostic procedure that can be adapted for point-of-care tests, and readily available for use throughout JEV endemic regions of the world. Improved diagnostic capabilities throughout JEV affected areas will not only benefit individual patients (through accurate diagnosis) but lead to higher quality surveillance data and a better understanding of the distribution of JE risk, enabling improved targeting and evaluation of interventions. The lack of diagnostic capabilities for JE is a barrier to understanding the actual disease burden and the impact of public health strategies.
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[^1]: According to official WHO data, although it is acknowledged that the People's Republic of China has performed widespread vaccination since 1971 ([@bib0280]). WPRO = Western Pacific Regional Office; SEARO = South-East Asia Regional Office.

[^2]: RT-PCR = reverse transcription-polymerase chain reaction; RNA = ribonucleic acid; CSF = cerebrospinal fluid; Ab = antibody; ELISA = enzyme-linked immunosorbent assay; HI = haemagglutination inhibition; CF = complement fixation test; IFA = indirect immunofluorescence assay.

[^3]: Confirmation of JE is categorized into levels 1-4 based on existing WHO and CDC criteria, such that level 1 provides the highest level of confidence.

[^4]: A total of 20,212 laboratory-confirmed JE cases were identified. Data are reported according to the year of publication. Inclusion criteria also required geographical (country) and temporal (year) data. Confirmatory levels of JE diagnosis detailed in [Table 2](#tbl0010){ref-type="table"}; level 1 provides the highest level of confidence, level 3 or 4 refers to cases that were reported as IgM detected in CSF and/or serum.

[^5]: G1 and 3 = genotype 1 and 3; NR = not reported; CSF = cerebrospinal fluid; PRNT = plaque reduction neutralization test; DENV = Dengue virus; VNT = viral neutralization test; FRNT = focus reduction neutralization test; TCID = median tissue culture infectious dose.

[^6]: titer required to reduce dengue viral plaques/focus/CPE by 50%, 80%, or 90%. MAC-ELISA = IgM antibody capture enzyme-linked immunosorbent assay, HI = haemagglutination assay, IIF = Indirect immunofluorescence assay.
